ALC vs NVS
Alcon Inc vs Novartis AG — AI-powered side-by-side comparison
| Metric | ALC | NVS |
|---|
| AI Score |
68
|
73
|
| Price |
$71.78
|
$156.34
|
| P/E Ratio |
43.26×
|
23.66×
|
| ROE |
4.4%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
74.3%
|
| Debt / Equity |
0.24×
|
1.18×
|
| Dividend Yield |
0.5%
|
2.9%
|
| RSI (14) |
66.2
|
55.8
|
| Beta |
0.703
|
0.46
|
| Expected Upside |
+14.1%
|
+2.7%
|
AI Committee View
Current Innellis committee reasoning for ALC versus NVS.
NVS leads by 5 points.
NVS scores 73/100 (Buy) versus ALC at 68/100 (Buy).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- No news coverage in the last 14 days -- limited independent confirmation either way — News
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical